Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT clinical trial. The trial is for evaluating OCU400, an investigational modifier gene therapy for retinitis pigmentosa, or RP. RP is a hereditary blinding disease.
According to Ocugen, the enrollment completion marks the transition from recruitment into the final phase of the trial ahead of a targeted 2027 approval. The trial enrolled 140 patients, randomized at a 2:1 ratio into a treatment group and an untreated control group, the company detailed. It added that the trial covers a broad range of RP gene mutations.
OCU400 is administered as a single injection per eye, Ocugen stated. The treatment works by targeting the NR2E3 nuclear hormone receptor gene, which regulates multiple retinal functions including photoreceptor development and cell survival. Rather than correcting a single mutation, Ocugen explained, the treatment aims to restore a dysfunctional gene network at the cellular level. This is what makes OCU400 gene-agnostic, which means it is designed to work across different genetic causes of RP rather than being limited to one specific mutation.
The trial’s primary endpoint is a 12-month change in visual function assessed by Luminance Dependent Navigation Assessment, or LDNA. This is a proprietary Ocugen mobility test measuring improvement in Lux Level from baseline. Ocugen expects topline data from this one-year trial in Q1 calendar year 2027.
Ocugen Inc. (NASDAQ:OCGN) is a biotechnology company. It focuses on developing therapies for eye diseases and gene therapies for rare disorders. Its pipeline includes OCU400, a modifier gene therapy for inherited retinal diseases, and OCU410, a treatment for dry age-related macular degeneration.
While we acknowledge the potential of OCGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Robinhood Stocks with High Potential and 15 Best Forever Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
